participant has already received full vaccination against sars- cov-2 2. prior administration of an investigational coronavirus (sars- cov, mers-cov) vaccine or current/planned simultaneous participation in another interventional study to either prevent or treat covid-19 3. participant has received/plans to receive a non-study vaccine within 14 days prior to or after any dose of ip 4. participant has a contraindication to im injections and blood draws (eg, bleeding disorders) 5. participants has a known or suspected allergy or history of anaphylaxis, urticaria or other significant adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine; refer to the ib) 6. subjects with previous positive pcr-test result for sars-cov-2 or positive anti-sars-cov-2 n protein antibody test 7. history of leukemia, lymphoma, or underlying bone marrow disorder (eg, myelodysplasia, myeloma, myeloproliferative disorder) or history of bone marrow transplant. 8. malignancy that required treatment with chemotherapy, immunotherapy, radiation therapy, or other antineoplastic target therapies within 24 months prior to study enrollment. 9. has participated in an interventional clinical study within 30 days prior to study inclusion

participant has already received full vaccination against sars- cov-2 2. prior administration of an investigational coronavirus (sars- cov, mers-cov) vaccine or current/planned simultaneous participation in another interventional study to either prevent or treat covid-19 3. participant has received/plans to receive a non-study vaccine within 14 days prior to or after any dose of ip 4. participant has a contraindication to im injections and blood draws (eg, bleeding disorders) 5. participants has a known or suspected allergy or history of anaphylaxis, urticaria or other significant adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine; refer to the ib) 6. subjects with previous positive pcr-test result for sars-cov-2 or positive anti-sars-cov-2 n protein antibody test 7. history of leukemia, lymphoma, or underlying bone marrow disorder (eg, myelodysplasia, myeloma, myeloproliferative disorder) or history of bone marrow transplant. 8. malignancy that required treatment with chemotherapy, immunotherapy, radiation therapy, or other antineoplastic target therapies within 24 months prior to study enrollment. 9. has participated in an interventional clinical study within 30 days prior to study inclusion